Tanzania has since 2006 stopped using sulphadoxine-pyrimethamine (SP) as the first line treatment drug for malaria. But the drug has not been totally condemned either. Studies are underway to look for evidence of protection of the SP when administered in conjunction with artemisinin compounds in combination with synthetic drugs (ACTs) in high transmission African context. A recent paper published in the Malaria Journal presents some evidence.